Opioid Use Disorder
Buprenorphine, methadone, naltrexone, fentanyl crisis.
The fourth wave of the overdose crisis — driven by illicitly manufactured fentanyl, fentanyl analogs, and the veterinary sedative xylazine — has reshaped opioid use disorder care. WCAM 2027 will examine high-dose buprenorphine inductions, microinduction (Bernese) and macroinduction protocols for fentanyl-tolerant patients, the post-X-waiver prescribing landscape, and emerging long-acting depot formulations (Sublocade, Brixadi). Sessions will also cover extended-release naltrexone retention strategies, methadone access reform under the updated 42 CFR Part 8, lofexidine for withdrawal, and the management of xylazine-associated wounds and protracted sedation now complicating fentanyl exposures.
- Buprenorphine microinduction and high-dose strategies for fentanyl
- Long-acting depot buprenorphine: Sublocade and Brixadi outcomes
- Methadone access post-42 CFR Part 8 reform and pharmacy dispensing pilots
- Extended-release naltrexone (Vivitrol): induction, retention, and reversal
- Xylazine-adulterated supply: wound care, withdrawal, and detection
- Lofexidine and adjunctive agents for opioid withdrawal
- MOUD in pregnancy: buprenorphine vs methadone and NOWS management